Roche CEO Hopes For Progress As China Tackles Approval Lag
This article was originally published in PharmAsia News
Recent signs that China is aiming to speed up its lengthy drug review processes are “encouraging” but there is still more to be done towards implementing “good and robust regulatory science” in the country, says Roche CEO Severin Schwan.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.